Literature DB >> 19408981

Secondary gliosarcoma: a review of clinical features and pathological diagnosis.

Seunggu J Han1, Isaac Yang, Tarik Tihan, Susan M Chang, Andrew T Parsa.   

Abstract

OBJECT: Although secondary gliosarcoma after treatment of primary glioblastoma multiforme has been described, little is known of these rare tumors. In this article the authors review the literature on secondary gliosarcoma, with attention to clinical course and pathological features.
METHODS: A PubMed search of the key word intracranial "gliosarcoma" with and without "radiation" or "radiotherapy" in humans was performed. The 204 citations yielded were screened for relevancy to gliosarcomas that occur after treatment of previous intracranial neoplasms.
RESULTS: A search of the literature yielded 24 relevant articles, combined for a total of only 12 cases of secondary gliosarcoma and 12 cases of radiation-induced gliosarcoma. Of the 12 cases of secondary gliosarcoma, all were previously treated with surgery and radiotherapy (mean dose 50.7 Gy), with a mean survival of 13 months since time of gliosarcoma diagnosis (range 6.9-19.4 months). In the cases of radiation-induced gliosarcoma, the mean dose of previous radiotherapy was 51.3 Gy (median 54 Gy, range 24-60 Gy), and the mean survival since gliosarcoma diagnosis was 6.7 months (median 6 months, range 2-10 months).
CONCLUSIONS: Secondary gliosarcoma and radiation-induced gliosarcoma are exceedingly rare. The literature on secondary gliosarcoma illustrates a more favorable survival than for primary gliosarcoma but remains limited regarding clinical and radiographic presentation, response to treatment, and pathogenesis. The results of the present review also support the notion that secondary gliosarcomas and radiation-induced gliosarcomas are distinct entities, with longer survival and shorter latency of gliosarcoma induction seen in the former. Efforts to elucidate the role of radiotherapy in the induction of gliosarcomas may yield new insights into therapeutic risks of cranial radiation and CNS tumor pathogenesis.

Entities:  

Mesh:

Year:  2010        PMID: 19408981     DOI: 10.3171/2009.3.JNS081081

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  22 in total

Review 1.  Therapeutic management of gliosarcoma in the temozolomide era.

Authors:  Mary Frances McAleer; Paul D Brown
Journal:  CNS Oncol       Date:  2015-04-23

2.  Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.

Authors:  Guobin Zhang; Shengyue Huang; Junting Zhang; Zhen Wu; Song Lin; Yonggang Wang
Journal:  J Neurooncol       Date:  2016-01-02       Impact factor: 4.130

3.  Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.

Authors:  David Cachia; Carlos Kamiya-Matsuoka; Jacob J Mandel; Adriana Olar; Matthew D Cykowski; Terri S Armstrong; Gregory N Fuller; Mark R Gilbert; John F De Groot
Journal:  J Neurooncol       Date:  2015-09-09       Impact factor: 4.130

4.  Cell-density-dependent manifestation of partial characteristics for neuronal precursors in a newly established human gliosarcoma cell line.

Authors:  Pei-Sen Yao; De-Zhi Kang; Xing-Fu Wang; Ru-Ying Lin; Zu-Cheng Ye
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-12-25       Impact factor: 2.416

5.  Sarcoma arising as a distinct nodule within glioblastoma: a morphological and molecular perspective on gliosarcoma.

Authors:  Cynthia Jimenez; Martin Powers; Andrew T Parsa; Christine Glastonbury; Jill M Hagenkord; Tarik Tihan
Journal:  J Neurooncol       Date:  2011-05-01       Impact factor: 4.130

6.  Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.

Authors:  Deborah R Smith; Cheng-Chia Wu; Heva J Saadatmand; Steven R Isaacson; Simon K Cheng; Michael B Sisti; Jeffrey N Bruce; Sameer A Sheth; Andrew B Lassman; Fabio M Iwamoto; Shih-Hsiu Wang; Peter Canoll; Guy M McKhann; Tony J C Wang
Journal:  J Neurooncol       Date:  2017-12-20       Impact factor: 4.130

7.  Case of glioblastoma patient treated with tumor treating fields therapy at recurrence degenerating to sarcoma.

Authors:  Pejman Majd; Daniel E O'Connell; Ronald C Kim; Daniela A Bota; Jose A Carrillo
Journal:  CNS Oncol       Date:  2017-03-17

8.  Radiotherapy plus concomitant temozolomide in primary gliosarcoma.

Authors:  Sebastian Adeberg; Denise Bernhardt; Semi Ben Harrabi; Christian Diehl; Christian Koelsche; Stefan Rieken; Andreas Unterberg; Andreas von Deimling; Juergen Debus
Journal:  J Neurooncol       Date:  2016-03-30       Impact factor: 4.130

9.  Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice.

Authors:  Gary V Walker; Mark R Gilbert; Sujit S Prabhu; Paul D Brown; Mary Frances McAleer
Journal:  J Neurooncol       Date:  2012-12-25       Impact factor: 4.130

10.  Secondary gliosarcoma after the treatment of primary glioblastoma multiforme.

Authors:  Khalid Andaloussi-Saghir; Mohamed Oukabli; Mohammed El Marjany; Hassan Sifat; Khalid Hadadi; Hamid Mansouri
Journal:  N Am J Med Sci       Date:  2011-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.